

A1
said dosage form providing a sustained release of said medicament after oral administration to human patients, said pH modifying agent facilitating the release of said medicament from said dosage form.

- A2
15. (Amended) The sustained release oral solid dosage form of claim 1, wherein said organic acid is selected from the group consisting of citric acid, succinic acid, fumaric acid, malic acid, maleic acid, glutaric acid, lactic acid, and combinations thereof.
16. (Amended) The sustained release oral solid dosage form of claim 1, wherein said organic acid is fumaric acid.
- A3
21. (Amended) The oral solid dosage form of claim 1, wherein said sustained release granulate further comprises a hydrophobic material.
- A4
24. (Amended) The oral solid dosage form of claim 5, wherein said sustained release granulate comprises from about 1 to about 20% by weight of said hydrophobic material.
- AS
42. (Amended) The oral solid dosage form of claim 40, wherein a sufficient amount of said granules to provide an effective dose of said medicament is disposed in a pharmaceutically acceptable capsule.
43. (Amended) The oral solid dosage form of claim 39, wherein at least part of a surface of said tablet is coated with a hydrophobic material to a weight gain of from about 1 to about 20 percent, by weight.
- Al
45. (Amended) The sustained release oral dosage form of claim 18, which provides a bimodal absorption profile of said medicament.

46. (Amended) A sustained release oral solid dosage form comprising a mixture of:
an effective amount of a calcium channel blocker to provide a therapeutic effect,
said calcium channel blocker having a solubility greater than 10 g/L;
a pH modifying agent comprising an organic acid;
a pharmaceutically acceptable surfactant; and
a sustained release granulate, the sustained release granulate comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid,
said dosage form providing a bimodal absorption profile of said calcium channel blocker and providing a sustained release of said calcium channel blocker for at least about 12 hours after oral administration to human patients, said pH modifying agent facilitating the release of said medicament from said dosage form.

61. (Amended) A sustained release oral solid dosage form comprising a mixture of:
an effective amount of oxybutynin or a pharmaceutically acceptable salt thereof to provide a therapeutic effect,
a pH modifying agent comprising an organic acid; and
a sustained release granulate, the sustained release granulate comprising a gelling agent, said gelling agent comprises a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum,
said dosage form providing a therapeutic effect for at least about 24 hours after administration to human patients, said pH modifying agent facilitating the release of said medicament from said dosage form.

Please add new claims 65-72 as follows:

sol. in what?

A

65. (New) A method of preparing a bioavailable sustained release oral solid dosage form for soluble to highly soluble therapeutically active medicaments; comprising:

how granulate

No help

a) preparing a sustained release granulate comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, thereafter

in what? don't use per Kunin b/c of partic. actives & their sol.

b) adding to said sustained release granulate a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l and a pH modifying agent comprising an organic acid that facilitates the release of said medicament from said dosage form to form a mixture; and

c) granulating and compressing the mixture of step b) into a solid dosage form, said dosage form providing a sustained release of said medicament after oral administration to human patients.

typo

X

66. (New) The method of claim 65, wherein said sustained release granulate further comprises up to about 20% by weight of an ionizable gel strength enhancing agent.

67. (New) The method of claim 65, wherein said sustained release granulate further comprises from about 1% to about 89% by weight of an inert diluent.

68. (New) The method of claim 65, wherein said sustained release granulate further comprises a surfactant.

69. (New) The method of claim 65, wherein said sustained release granulate further comprises from about 1% to about 20% by weight of a hydrophobic material.